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a b s t r a c t
People with diabetes display biomechanical gait alterations compared to controls and have a higher
metabolic cost of walking (CoW), but it remains unknown whether differences in the vertical displace-
ment of the body centre of mass (CoM) may play a role in this higher CoW. The aim of this study was
to investigate vertical CoM displacement (and step length as a potential underpinning factor) as an
explanatory factor in the previously observed increased CoWwith diabetes. Thirty-one non-diabetic con-
trols (Ctrl); 22 diabetic patients without peripheral neuropathy (DM) and 14 patients with moderate/sev-
ere Diabetic Peripheral Neuropathy (DPN), underwent gait analysis using a motion analysis system and
force plates while walking at a range of matched speeds between 0.6 and 1.6 m/s. Vertical displacement
of the CoM was measured over the gait cycle, and was not different in either diabetes patients with or
without diabetic peripheral neuropathy compared to controls across the range of matched walking
speeds examined (at 1 m/s: Ctrl: 5.59 (SD: 1.6), DM: 5.41 (1.63), DPN: 4.91 (1.66) cm; p > 0.05). The
DPN group displayed significantly shorter steps (at 1 m/s: Ctrl: 69, DM: 67, DPN: 64 cm; p > 0.05) and
higher cadence (at 1 m/s: Ctrl: 117 (SD1.12), DM: 119 (1.08), DPN: 122 (1.25) steps per minute;
p > 0.05) across all walking speeds compared to controls. The vertical CoM displacement is therefore unli-
kely to be a factor in itself that contributes towards the higher CoW observed recently in people with dia-
betic neuropathy. The higher CoW in patients with diabetes may not be explained by the CoM
displacement, but rather may be more related to shorter step lengths, increased cadence and the associ-
ated increased internal work and higher muscle forces developed by walking with more flexed joints.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Diabetes is a global epidemic with significant morbidity and
particularly common with increasing age (International Diabetes
Federation, 2013). Diabetes is associated with a range of serious
complications that result in reduced quality of life and premature
mortality. Diabetic peripheral neuropathy (DPN) is one of the most
severe complications of diabetes, occurring in 30–50% of all dia-
betic patients (Cappozzo, 1981). The main cause is neurovascular
alterations to the nerve fibres and blood vessels supplying the
nerve endings, resulting in reduced or absent nerve conduction
(Diabetes UK: Diabetes in the UK 2011/12: Key Statistics on Dia-
betes. 2014.). The European association for the study of diabetes
defines DPN as ‘‘the presence of symptoms and/or signs of periph-
eral nerve dysfunction in people with diabetes after the exclusion
of other causes” (Boulton, 2005). DPN-related changes in the lower
limbs lead to functional gait adaptations including taking shorter
steps, having a higher cadence but slower self-selected and maxi-
mum walking speed (Brown et al., 2014; Chiles et al., 2014; Ko
et al., 2011; Menz et al., 2004; Raspovic, 2013; Sawacha et al.,
2009). Consistently smaller ranges of motion at the ankle, knee
and hip in the DPN group have been reported from a range of stud-
ies and likely underlies the shorter step length reported in diabetes
patients (Abate et al., 2012; Gomes et al., 2001; Martinelli et al.,
2013; Raspovic, 2013; Sacco and Amadio, 2002). Other major gait
adaptations include reduced range of joint movement (Andersen,
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2012) and reduced muscle strength and power characteristics
(Brown et al., 2014).
We have recently shown how the metabolic cost of walking
(CoW) is higher in people with diabetes and particularly in those
with DPN compared to controls (Petrovic et al., 2016). During
walking, mechanical work is done to continuously raise and lower
the body centre of mass (CoM), which requires metabolic energy
expenditure. The CoM in the human body moves like an inverted
pendulum during walking, with the pendulum action conserving
mechanical energy (Alexander, 1991). More specifically, by keep-
ing the knee relatively straight during the single leg stance phase
of gait, giving rise to the arc of the CoM, the leg supports body mass
with relatively little muscular force.
Like an inverted pendulum, the CoM rises/decelerates in the
first half of the stance phase and then falls/accelerates during the
second half of the stance phase (Candrilli et al., 2007; Lamoreux,
1972; Lee and Farley, 1988; Thorstensson and Roberthson, 1987).
Consequently, in the first half of the stance phase, kinetic energy
is converted into gravitational potential energy (Cavagna et al.,
1976; Cavagna and Franzetti, 1986), whereas in the second half
of the stance phase, the opposite conversion occurs. Over the gait
cycle, the CoM has a sinusoidal pattern in the vertical direction
with two peaks occurring. The first vertical peak of the CoM occurs
around 30% of the gait cycle during single-limb stance as the CoM
is ‘vaulted’ over the straight stance limb in an inverted pendulum
manner, while the second peak occurs around 80% of the gait cycle
during the terminal mid-stance phase.
Increasing the CoM displacement in a type of up and down
‘bobbing’ action leads to an increase in the CoW compared to a nor-
mal gait (Neptune et al., 2004; Massaad et al., 2007). Equally, if gait
is manipulated to minimise or eliminate any vertical displacement
of the CoM by walking in a ‘crouched’ style with very flexed limbs,
there is an increase in the CoW compared to normal gait (Ortega
and Farley, 2007; Massaad et al., 2007; Gordon et al., 2009). Hence,
there appears to be an ‘optimum’ vertical displacement for the
CoM in terms of its effect on the metabolic CoW, where deviations
from this optimum seem inefficient in terms of energy cost.
Stride length also seems intrinsically linked to the CoM vertical
displacement and the associated CoW. It has been shown that
stride lengths greater than the optimal, increase the CoM vertical
displacement and increase the CoW, while stride lengths lower
than the optimal, reduce the vertical displacement of the CoM,
but also increase the CoW (Gordon et al., 2009). Since it is known
that diabetes patients take shorter steps compared to controls, it
might be hypothesised that that this would reduce the vertical dis-
placement of the CoM, thereby increasing the CoW. Because walk-
ing speed may be a confounding factor in the relationship between
step length and CoM displacement, in the present study we choose
to compare the CoM vertical displacement at matched walking
speeds between patients with diabetes and controls. Therefore,
this study examined the vertical displacement of the CoM while
walking at a range of matched speeds between 0.6 and 1.6 m/s.
We hypothesised that diabetes patients would have a reduced ver-
tical CoM displacement that might explain our recent findings of a
greater CoW, with a reduced step length being a potential factor
underpinning the suggested CoM behaviour.
2. Materials and methods
2.1. Participants
After receiving ethical approval from all relevant bodies, 67 par-
ticipants gave written informed consent to participate in this
study. All procedures in this study complied with the declaration
of Helsinki. All participants were allocated into one of three
groups: patients with diabetes and moderate-severe peripheral
neuropathy (DPN, n = 14, 14 men), patients with diabetes but no
peripheral neuropathy (DM, n = 22, 12 men) and healthy controls
without diabetes or peripheral neuropathy (Ctrl, n = 31, 19 men).
The same participant cohort was examined to establish the meta-
bolic CoW and reported in references (Petrovic et al., 2016). The
CoW was significantly higher particularly in the DPN group com-
pared with controls and also in the DM group compared with con-
trols, across a range of matched walking speeds.
All participants were assessed to confirm they satisfied the
inclusion criteria for each group. Major exclusion criteria for par-
ticipation in the study included peripheral vascular disease, mus-
culoskeletal injury or recent surgery affecting gait, any
amputation other than 1 or 2 lesser toes and open foot ulcer. A ran-
dom blood glucose test was performed in the Ctrl group to confirm
the absence of diabetes (<7 mmol/l) and the below neuropathy
tests conducted to confirm the absence of neuropathy in the Con-
trols. The majority of the DM and the DPN patients reported taking
insulin, cholesterol-lowering medication and diabetes medication,
while from the whole sample (including controls) only 2 people
reported smoking.
2.2. Assessment of peripheral neuropathy
A clinical evaluation was undertaken to quantify peripheral
neuropathy in diabetic patients and to confirm the absence of neu-
ropathy in healthy controls. Peripheral neuropathy was assessed
by using the modified Neuropathy Disability Score (mNDS) and
the vibration perception threshold (VPT). The mNDS is a combined
score taken from tests measuring the patient’s ability to detect
temperature, pain, vibration and the Achilles tendon reflex
(Boulton, 2005). The VPT was assessed by placing the probe of
the biothesiometer (Biomedical Instrument Co, Newbury, OH,
USA) on the apex of the hallux and increasing the level of vibration
until detected by the participant. Patients were defined as having
moderate-to-severe neuropathy and classed as DPN if in either
one or both of their feet they displayed either an mNDS score of
6 or a VPT of 25 V (or both).
2.3. Gait analysis
Participants were asked to walk along a 10-metre walkway in
the gait laboratory at a series of standardised speeds (0.6, 0.8,
1.0, 1.2, 1.4 and 1.6 m/s). The standardised walking speeds were
controlled by measuring the velocity of a marker attached to the
sacrum after each trial from the motion analysis data and provid-
ing immediate feedback for participants as to whether they needed
to walk more quickly or more slowly on the next trial to achieve
the required speed. The participant’s starting position was altered
by the experimenter to ensure a ‘clean’ (i.e., no overlap outside the
force platform) foot-strike on one or two of the force platforms
(positioned in the middle of the walkway) per walking trial with-
out alteration to their natural gait. Walking trials were repeated
until at least three ‘clean’ foot contacts with the force platforms
were made with each limb, for each walking speed condition. Kine-
matics were collected at 100 Hz using a 10-camera Vicon motion
capture system (Vicon, Oxford, UK) positioned around the 10-
meter walkway, tracking a full-body modified Plug-In-Gait marker
set consisting of 54 markers. Where possible markers were placed
directly onto the skin; to minimise movement artefacts resulting
from loose clothing all participants wore tight-fitting shorts and
tops. All participants wore specialist diabetic shoes (MedSurg,
Darco, Raisting, Germany) with a neutral foot-bed (no rocker bot-
tom outsole), ensuring the diabetic patients walked with safe,
appropriate footwear whilst minimising the effect of footwear by
standardising across all participants.
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2.4. Centre of mass displacement
Gait variables (stride length, step length and cadence, vertical
displacement of the CoM) were calculated from the kinematic data
using Visual 3D software (C-motion Inc., MD, USA). Motion data
collected during gait analysis were processed, and Dempster’s seg-
ment parameter model (1955) was used to calculate mass distribu-
tion for each body segment, thereby allowing accurate calculation
of the entire body centre of mass. The vertical displacement of the
CoM was calculated as the maximum range of vertical displace-
ment (minimum to maximum peak) of the CoM (Fig. 2) during
the whole gait cycle, using the mean of the three trials from each
person.
2.5. Statistics
A one-way analysis of variance (ANOVA) was performed for all
variables to assess between group differences. If the ANOVA was
significant, a Fisher’s least significant difference (LSD) post-hoc test
was used to test for differences between the diabetes groups (DM
and DPN) and the control group. All values presented are means
and standard deviation. Significance was set at p < 0.05. The power
analysis identified minimum group sizes of n = 7, for an effect size
0.71 (b = 0.1, a = 1%). Analysis of covariance was used to assess the
effect of body mass on CoM excursion.
Pearson product-moment correlation coefficients were calcu-
lated at each walking speed (and all walking speeds combined)
using data from participants in all three experimental groups to
determine whether there was a significant correlation between
the CoM vertical displacement and the cost of walking (previously
published data on CoW, Petrovic et al., 2016).
3. Results
3.1. Participant characteristics
There were significant differences between the groups in age,
body mass and BMI, which were significantly greater in the DPN
group (Table 1, p < 0.01).
3.2. Step length and cadence
The DPN group displayed significantly shorter step lengths
across all speeds compared to the Ctrl group (Table 2). The DPN
group had significantly higher cadence across all speeds compared
to the control group.
3.3. Centre of mass displacement at different speeds
Across all matched speeds there were no significant differences
in the CoM vertical displacement between groups (Fig. 1; Table 3),
neither when including a body mass as a covariate.
Pearson’s correlations only reached significance at walking
speeds of 0.8 and 1.6 m/s, but the r values were consistently low
across speeds ranging between 0.287 and 0.262 (Table 4). When
combining data for all participants, across all walking speeds Pear-
son’s correlation failed to reach significance, with an r value of
0.08 (Table 4, Fig. 3).
4. Discussion
This study has shown for the first time that the vertical dis-
placement of the CoM during walking is not different between dia-
betes patients with and without diabetic peripheral neuropathy
compared to controls across a range of matched speeds (Fig. 1)
and is therefore unlikely to be a factor in itself that contributes
towards the increased CoW observed recently (Petrovic et al.,
2016) on the same data set in people with diabetic peripheral neu-
ropathy (at 1.2 m/s: Ctrl: 2.18 (SD: 0.67), DM: 2.20 (0.81), DPN:
2.35 (1.76) Jkg1m1; p > 0.05). Furthermore, the relationship
between the CoM and CoW was very weak across all walking
speeds (Table 4, Fig. 3), indicating no clear link between these
two variables across participant groups in the present study.
It has previously been shown that stride lengths shorter and
longer than the optimum lead to reduced and increased CoM dis-
placements, respectively, but increasing the metabolic CoW in both
situations (Gordon et al., 2009). In this previous study, participants
increased their metabolic cost when they reduced their vertical
CoM movement by taking shorter strides. Participants also
expended more metabolic energy when they walked with a greater
stride length than their preferred stride length. Previous work
Table 1
Participant characteristics and results from neuropathy assessments.
Variable Group
Ctrl DM DPN
Age (yr) 56 (10) 51 (9)** 66 (14)**
Body mass (kg) 76 (10) 80.5 (12) 91.5 (18)**
Height (m) 1.72 (0.12) 1.71 (0.09) 1.73 (0.11)
BMI (kg/m2) 26 (3) 28 (4) 31 (4)**
NDS (Score/10) 1 (1) 2 (1) 7 (2)**
VPT (Volts) 6.1 (3.4) 8.2 (3.4) 27.4 (9.1)**
Diabetes duration (years) – 14 (12) 14 (11)
Type 1 diabetes (n) – 7 4
Type 2 diabetes (n) – 15 10
Healthy controls (Ctrl, n = 31), diabetic patients with no neuropathy (DM, n = 22)
and diabetic patients with moderate/severe neuropathy (DPN, n = 14). BMI = body
mass index, NDS = neuropathy disability score, VPT = vibration perception thresh-
old. Values are means (standard deviations).
** Significant differences from the Ctrl group are denoted by P < 0.01.
Table 2
Temporal-spatial gait parameters.
Variable Group
Ctrl DM DPN
0.6 m/s
Step length (m) 0.59 (0.12) 0.57 (0.12) 0.51 (0.09)**
Cadence (steps/m) 108 (0.61) 108 (0.74) 113 (0.41)**
0.8 m/s
Step length (m) 0.63 (0.14) 0.57 (0.12) 0.53 (0.15)**
Cadence (steps/m) 112 (0.84) 113 (0.67) 116 (0.68)**
1.0 m/s
Step length (m) 0.69 (0.15) 0.67 (0.05) 0.64 (0.04)*
Cadence (steps/m) 117 (1.12) 119 (1.08) 122 (1.25)**
1.2 m/s
Step length (m) 0.76 (0.11) 0.75 (0.17) 0.69 (0.07)*
Cadence (steps/m) 124 (1.16) 125 (1.27) 128 (1.08)**
1.4 m/s
Step length (m) 0.79 (0.12) 0.77 (0.17) 0.71 (0.11)*
Cadence (steps/m) 127 (1.56) 129 (1.47) 131 (1.49)**
1.6 m/s
Step length (m) 0.81 (0.11) 0.80 (0.04) 0.74 (0.02)*
Cadence (steps/m) 129 (0.98) 132 (0.48) 135 (0.63)**
Maximum walking speed (m/s) 1.92 (0.11) 1.88(0.16)** 1.68 (0.22)**
Step length (m) 0.85 (0.07) 0.79 (0.06)* 0.78 (0.12)**
Cadence (steps/m) 143 (1.18) 140 (1.27)* 129 (0.98)**
Healthy controls (Ctrl, n = 31), diabetic patients with no neuropathy (DM, n = 22)
and diabetic patients with moderate/severe neuropathy (DPN, n = 14). Values are
means (standard deviations). Gait parameters were collected on the laboratory
walkway.
* Significant differences from the Ctrl group are denoted by P < 0.05.
** Significant differences from the Ctrl group are denoted by P < 0.01.
M. Petrovic et al. / Journal of Biomechanics 83 (2019) 85–90 87
(Donelan et al., 2002) has shown that as stride length increases,
metabolic energy expenditure and mechanical work performed
on the CoM also increase. This is not caused by CoM displacement
per se but rather by the additional negative work performed to
redirect the CoM velocity during step-to-step transitions and by
positive work to restore the energy lost. Although we did find con-
sistently shorter step lengths across matched walking speeds in
patients with diabetes and particularly those with diabetic periph-
eral neuropathy compared to controls, this did not alter the vertical
displacement of the CoM compared to controls (Fig. 1).
The lack of effect of stride shortening on the CoM in the present
study might be due to the fact that people with diabetes and dia-
betic peripheral neuropathy have adapted to a different optimal
step length, which is consistently shorter compared to controls
across the range of walking speeds examined. Alternatively, they
could have adopted a different step length based on the total meta-
bolic CoW rather than the cost associated with CoM displacement.
Consistent with the shorter steps taken by both diabetes groups
compared to controls, was the higher cadence required to meet
the prescribed matched walking speeds by the diabetes patients
(Table 2). An increased cadence in the diabetes groups would
require greater internal work from the muscles to move the legs
during walking (Minetti et al., 1994). Although we have previously
found (Petrovic et al., 2016) the joint work developed during a sin-
gle stance phase to be lower in patients with diabetes and even
more so in those with diabetic peripheral neuropathy, this would
be repeated more often over a given distance in diabetes patients
because of a higher cadence. Therefore, a higher cadence for any
given walking speed could explain the higher CoW previously
reported in patients with diabetes and those with diabetic periph-
eral neuropathy through greater cumulative joint work (Petrovic
et al., 2016).
In the absence of differences in the CoM vertical displacement,
another possible explanation for the higher CoW previously
reported in diabetes patients is that they might be producing
greater muscle force without performing as much joint work per
stance phase. This would be consistent with previous reports from
walking with a ‘crouched gait’ by excessively flexing the joints
(Massaad et al., 2007; Ortega and Farley, 2007). Diabetes patients
were observed to walk with shorter steps, which is known to be
achieved by greater flexion in the lower limb joints. This likely
gives rise to higher muscle forces to sustain the more flexed joint
positions as previously observed (Sasaki et al., 2009) and conse-
quently a higher metabolic CoW. Therefore, the effective mechan-
ical advantage (muscle force moment arm/ground reaction force
moment arm) may be less favourable in diabetic patients
(Petrovic et al., 2017), which would mean that more muscle force
would be required to overcome the moment of the ground reaction
Fig. 1. Centre of mass (CoM) vertical (Z) displacement across walking speeds from 0.6 to 1.6 m/s and maximum walking speed for healthy controls (Ctrl; n = 31), diabetic
patients with no neuropathy (DM; n = 22) and diabetic patients with moderate/severe neuropathy (DPN; n = 14). Values are group means and SD; ** denotes significantly
(P < 0.01) different from the control group.
Fig. 2. Example trace from one participant showing the vertical displacement of the
centre of mass over the gait cycle. The vertical displacement values reported in the
present study reflect the minimum to maximum peak value.
Table 3
Vertical displacement of the CoM and between-group differences.
Walking speed Ctrl (cm) DM (cm) DPN (cm) Diff Ctrl-DM (%) Diff Ctrl-DPN (%)
0.6 m/s 4.64 (1.51) 4.43 (1.52) 4.50 (1.49) 4.60 3.00
0.8 m/s 4.53 (1.55) 4.65 (1.56) 4.71 (1.59) 2.71 3.97
1 m/s 5.59 (1.60) 5.41 (1.63) 4.91 (1.66) 3.25 12.14
1.2 m/s 6.19 (1.63) 5.77 (1.68) 4.75 (1.74) 6.78 23.32
1.4 m/s 6.68 (1.71) 6.13 (1.70) 6.07 (1.79) 8.23 9.23
1.6 m/s 7.09 (1.79) 6.73 (1.76) 7.30 (1.82) 5.01 3.03
MAX 6.43 (1.87) 6.07 (1.85) 7.73 (1.88) 5.60 20.22
Centre of mass (CoM) vertical displacement across walking speeds from 0.6 to 1.6 m/s and maximum walking speed for healthy controls (Ctrl, n = 31), diabetic patients with
no neuropathy (DM, n = 22) and diabetic patients with moderate/severe neuropathy (DPN, n = 14). Values are means (standard deviations).
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force – hence higher CoW. This factor may also explain why dia-
betes patients have adopted an ‘‘optimum” CoM displacement
(meaning unaltered compared to controls) per stride length as a
strategy to minimise CoW. Gordon et al. (2009) presented in their
study a manipulation of step length above and below the optimal
and found that the CoM vertical displacement increases and
decreases over that observed at the self-selected step length. Both
of these situations were associated with a higher metabolic CoW
compared to that observed at self-selected step length, suggesting
an optimal vertical displacement of the CoM where energy cost is
minimised. People who are at higher risk of falls have been shown
to take shorter steps (Karamanidis et al., 2008; Schillings et al.,
2005) as part of a more cautious strategy to walking, which could
be one of a number of potential factors causing them to walk with
shorter steps. Another potential reason could relate to reduced
ankle range of movement, reduced Achilles tendon elongation
and increased Achilles tendon stiffness during walking as we have
recently shown (Petrovic et al., 2018).
Other factors contributing to an increased metabolic CoW in
patients with diabetes and diabetic peripheral neuropathy could
include increased muscle co-activation, which has been shown in
older adults without diabetes (Cronin et al., 2010; Mian et al.,
2007) and an increased Achilles tendon stiffness (Petrovic et al.,
2018). Indeed, we have recently shown how Achilles tendon stiff-
ness is higher in people with diabetes and particularly those with
diabetic peripheral neuropathy compared to controls during walk-
ing (Petrovic et al., 2018). An increased Achilles tendon stiffness
would reduce the elastic energy stored from this long tendon dur-
ing walking, requiring a relatively greater energy contribution from
the plantar flexor muscles, increasing the metabolic CoW.
To the best of our knowledge this is the first study that has
investigated the CoM displacement during walking in a diabetic
patient population. It could be considered as a limitation of the
present study that body mass was significantly different between
groups. However, the higher body mass of patients with diabetes
(especially those with DPN) is a well-known characteristic of this
population described in the literature (Ijzerman et al., 2011;
Jor’dan et al., 2014) and is unlikely to have directly affected the
CoM vertical displacement. If anything, it might be expected that
increased body mass might reduce the extent to which the CoM
is displaced, but this was not found in the present study indicating
that group differences in body mass did not influence the present
results. Although only a mean of 10 years difference, patients in
the DPN group were significantly older than controls (66–56 years,
respectively), which might be considered a confounding factor for
some of the variables examined.
We have shown that there are no differences in the vertical dis-
placement of the CoM in patients with diabetes compared with
controls when walking speed is matched and no relationship
between the CoM vertical displacement and the CoW. The higher
CoW in patients with diabetes may not be explained by the vertical
CoM displacement, but rather may be more related to shorter step
lengths, increased cadence and the associated increased internal
work and higher muscles forces developed by walking with more
flexed joints.
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Fig. 3. Individual data points for all participants from all three experimental groups
(DPN, DM and Ctrl, n = 67) and at all measured walking speeds (speed from 0.6 to
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